Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745840/ https://www.ncbi.nlm.nih.gov/pubmed/23983687 http://dx.doi.org/10.1155/2013/517239 |
_version_ | 1782280740673683456 |
---|---|
author | Walentowicz, Pawel Sadlecki, Pawel Krintus, Magdalena Sypniewska, Grazyna Mankowska-Cyl, Aneta Grabiec, Marek Walentowicz-Sadlecka, Malgorzata |
author_facet | Walentowicz, Pawel Sadlecki, Pawel Krintus, Magdalena Sypniewska, Grazyna Mankowska-Cyl, Aneta Grabiec, Marek Walentowicz-Sadlecka, Malgorzata |
author_sort | Walentowicz, Pawel |
collection | PubMed |
description | Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45–79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0–0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15–0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading (P > 0.05). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer. |
format | Online Article Text |
id | pubmed-3745840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37458402013-08-27 Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer Walentowicz, Pawel Sadlecki, Pawel Krintus, Magdalena Sypniewska, Grazyna Mankowska-Cyl, Aneta Grabiec, Marek Walentowicz-Sadlecka, Malgorzata Int J Endocrinol Research Article Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45–79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0–0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15–0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading (P > 0.05). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer. Hindawi Publishing Corporation 2013 2013-07-28 /pmc/articles/PMC3745840/ /pubmed/23983687 http://dx.doi.org/10.1155/2013/517239 Text en Copyright © 2013 Pawel Walentowicz et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Walentowicz, Pawel Sadlecki, Pawel Krintus, Magdalena Sypniewska, Grazyna Mankowska-Cyl, Aneta Grabiec, Marek Walentowicz-Sadlecka, Malgorzata Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer |
title | Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer |
title_full | Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer |
title_fullStr | Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer |
title_full_unstemmed | Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer |
title_short | Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer |
title_sort | serum anti-müllerian hormone levels in patients with epithelial ovarian cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745840/ https://www.ncbi.nlm.nih.gov/pubmed/23983687 http://dx.doi.org/10.1155/2013/517239 |
work_keys_str_mv | AT walentowiczpawel serumantimullerianhormonelevelsinpatientswithepithelialovariancancer AT sadleckipawel serumantimullerianhormonelevelsinpatientswithepithelialovariancancer AT krintusmagdalena serumantimullerianhormonelevelsinpatientswithepithelialovariancancer AT sypniewskagrazyna serumantimullerianhormonelevelsinpatientswithepithelialovariancancer AT mankowskacylaneta serumantimullerianhormonelevelsinpatientswithepithelialovariancancer AT grabiecmarek serumantimullerianhormonelevelsinpatientswithepithelialovariancancer AT walentowiczsadleckamalgorzata serumantimullerianhormonelevelsinpatientswithepithelialovariancancer |